Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes

Vox Sanguinis

Volumn 112, Issue 1, 2017, Pages 79-86

  Lin, Y ^a,b   Saskin, A ^c   Wells, R A ^a,b,c   Lenis, M ^c   Mamedov, A ^c   Callum, J ^a,b   Buckstein, R ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

myelodysplastic syndromes; red blood cell antigens and antibodies; red cell components; transfusion therapy

Indexed keywords

ALLOANTIBODY; RHESUS ANTIGEN; BLOOD GROUP RHESUS SYSTEM;

AGED; ALLOIMMUNIZATION; ARTICLE; BLOOD GROUP KELL SYSTEM; BLOOD GROUP RHESUS SYSTEM; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; CLASSIFICATION; ERYTHROCYTE; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; REGISTER;

AGED; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HUMANS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; PHENOTYPE; REGISTRIES; RETROSPECTIVE STUDIES; RH-HR BLOOD-GROUP SYSTEM;

EID: 84995602511     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12455     Document Type: Article

References (20)

1. McQuilten ZK, Polizzotto MN, Wood EM, et al.: Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion 2013; 53:1714–1721
2. Balducci L: Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006; 106:2087–2094
3. Gupta P, LeRoy SC, Luikart SD, et al.: Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999; 23:953–959
4. Sanz C, Nomdedeu M, Belkaid M, et al.: Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013; 53:710–715
5. Aygun B, Padmanabhan S, Paley C, et al.: Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42:37–43
6. Vichinsky EP, Earles A, Johnson RA, et al.: Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617–1621
7. Vichinsky EP, Luban NL, Wright E, et al.: Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086–1092
8. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al.: Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033–1048
9. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079–2088
10. Greenberg PL, Tuechler H, Schanz J, et al.: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454–2465
11. Rozovski U, Ben-Tal O, Kirgner I, et al.: Increased Incidence of red blood cell alloantibodies in myelodysplastic syndrome. Isr Med Assoc J 2015; 17:624–627
12. Adams RJ, McKie VC, Brambilla D, et al.: Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998; 19:110–129
13. Lasalle-Williams M, Nuss R, Le T, et al.: Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51:1732–1739
14. Miller ST, Kim HY, Weiner DL, et al.: Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013; 53:704–709
15. Kacker S, Ness PM, Savage WJ, et al.: Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54:86–97
16. Webb J, Chou ST: Prospective antigen matching strategies fail to fit the model. Transfusion 2015; 55:221–222
17. van Hulst M, de Wolf JT, Staginnus U, et al.: Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83:146–155
18. Kamphuis MM, Lindenburg I, van Kamp IL, et al.: Implementation of routine screening for Kell antibodies: does it improve perinatal survival? Transfusion 2008; 48:953–957
19. British Committee for Standards in H, Milkins C, Berryman J, et al.: Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories British Committee for Standards in Haematology. Transfus Med 2013; 23: 3–35
20. Bennardello F, Coluzzi S, Curciarello G, et al.: Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus 2015; 13:109–134